Organisation paid for research Program year 2025 Source: CMS Open Payments

Bradenton Research Center Inc

Neither a doctor nor a teaching hospital

Research payments

$5,514,595

248 payments

Through program year 2025, Bradenton Research Center Inc is reported as receiving $5,514,595 in research payments, across 248 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,259,308 16
2024 Research $668,524 24
2023 Research $878,425 27
2022 Research $722,721 19
2021 Research $202,715 27
2020 Research $846,592 52
2019 Research $936,311 83

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,310,559 31 payments
  2. Genentech, Inc. $1,033,823 120 payments
  3. Novartis Pharmaceuticals Corporation $346,301 4 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $226,781 11 payments
  5. Sage Therapeutics, Inc. $114,368 4 payments
  6. Ucb SA $90,638 7 payments
  7. Horizon Therapeutics plc $88,654 3 payments
  8. Gilead Sciences, Inc. $87,436 13 payments
  9. Amgen Inc. $74,788 4 payments
  10. Roche Products Limited $69,265 23 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $699,418 5 payments
  2. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $668,146 2 payments
  3. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $655,884 6 payments
  4. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $612,892 3 payments
  5. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $501,525 2 payments
  6. Gantenerumab in Early Ad $446,356 27 payments
  7. Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $346,301 4 payments
  8. Postgraduate Roll Over Study $207,152 16 payments
  9. Phase II Study of Anti Tau in Prodromal to Mild Ad $173,146 44 payments
  10. Donanemab Follow-On Study: Safety, Tolerability, and Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments $141,892 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record